India, March 19 -- HUTCHMED (China) Limited (HCM) announced positive results from the SAVANNAH Phase II trial, which showed high and durable response rates with the combination of savolitinib and TAGRISSO in MET-high lung cancer. This highlights a promising chemo-free oral treatment strategy to address resistance mechanisms in advanced settings. Additionally, long-term survival benefits and safety were observed in the savolitinib Phase IIIb study for METex14 non-small cell lung cancer.
The company announced that new and updated data from several studies of compounds discovered by the company, savolitinib and surufatinib, will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place on March 26-29, 2025 in Paris, France....